<SEC-DOCUMENT>0001683168-26-003004.txt : 20260415
<SEC-HEADER>0001683168-26-003004.hdr.sgml : 20260415
<ACCEPTANCE-DATETIME>20260415171033
ACCESSION NUMBER:		0001683168-26-003004
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20260415
DATE AS OF CHANGE:		20260415

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tivic Health Systems, Inc.
		CENTRAL INDEX KEY:			0001787740
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				814016391
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-295029
		FILM NUMBER:		26864875

	BUSINESS ADDRESS:	
		STREET 1:		1305 E. HOUSTON STREET
		STREET 2:		BUILDING 1, SUITE 311
		CITY:			SAN ANTONIO
		STATE:			TX
		BUSINESS PHONE:		(888)276-6888

	MAIL ADDRESS:	
		STREET 1:		1305 E. HOUSTON STREET
		STREET 2:		BUILDING 1, SUITE 311
		CITY:			SAN ANTONIO
		STATE:			TX
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>tivic_424b3.htm
<DESCRIPTION>PROSPECTUS
<TEXT>
<HTML>
<HEAD>
     <TITLE>Tivic Health Systems, Inc. S-1</TITLE>

</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(3)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-295029</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROSPECTUS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<IMG SRC="image_001.jpg" ALT="" STYLE="height: 49px; width: 314px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>956,222 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus relates to the offer and
resale by Tumim Stone Capital, LLC (&#8220;Tumim&#8221; or the &#8220;Selling Stockholder&#8221;) of up to an aggregate of 956,222
shares (the &#8220;Shares&#8221;) of common stock, par value $0.0001 per share, of Tivic Health Systems, Inc. (the
&#8220;Company&#8221;), consisting of (i) 519,210 shares of our common stock which we may sell and issue to Tumim from time to time
pursuant to the Common Stock Purchase Agreement we entered into with Tumim on February 6, 2026 (the &#8220;Purchase
Agreement&#8221;), and (ii) 437,012 shares of common stock issuable upon exercise of a pre-funded warrant to purchase 437,012 shares
of common stock we issued to Tumim on February 6, 2026 as commitment pre-funded warrants (the &#8220;Commitment Pre-Funded
Warrant&#8221;) in connection with execution of the Purchase Agreement. See the sections of this prospectus titled &#8220;<A HREF="#drs_007">The
Tumim Transaction</A>&#8221; for additional information regarding the Purchase Agreement and the transactions contemplated thereby
and &#8220;<A HREF="#drs_009">Selling Stockholder</A>&#8221; for additional information regarding Tumim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are registering the offer and sale of these
securities to satisfy certain registration rights we have granted to Tumim. We are not selling any securities under this prospectus and
will not receive any of the proceeds from the sale of shares of common stock by the Selling Stockholder. However, we may receive gross
proceeds of up to $50.0 million from the sales, if any, of shares of our common stock to the Selling Stockholder pursuant to the Purchase
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholder may sell, or otherwise
dispose of, the shares of common stock described in this prospectus in a number of different ways and at varying prices. The Selling Stockholder
is an &#8220;underwriter&#8221; within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;), in connection with the resale shares of our common stock under this prospectus and any broker-dealers or agents that are
involved in such resales may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection therewith.
In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares purchased by them
may be deemed to be underwriting commissions or discounts under the Securities Act. See the section titled &#8220;<A HREF="#drs_010">Plan of Distribution</A>&#8221;
beginning on page 16 of this prospectus for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is traded on The Nasdaq Capital
Market tier of The Nasdaq Stock Market, LLC under the symbol &#8220;TIVC.&#8221; The last reported sale price of our common stock on the
Nasdaq Capital Market on April 8, 2026 was $1.03 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should read this prospectus, together with
additional information described under the headings &#8220;<A HREF="#drs_016">Where You Can Find Additional Information</A>&#8221; and &#8220;<A HREF="#drs_015">Incorporation of Certain Information by Reference</A>&#8221; carefully before you invest in any of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We are an &#8220;emerging growth company&#8221;
and a &#8220;smaller reporting company,&#8221; each as defined under the federal securities laws and, as such, have elected to comply
with certain reduced reporting requirements for this prospectus and may elect to do so in future filings. See the section titled &#8220;<A HREF="#drs_018">Implications of Being an Emerging Growth Company and a Smaller Reporting Company</A>.&#8221;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our securities involves a high
degree of risk. Before making an investment decision, please read the section titled &#8220;<A HREF="#drs_006">Risk Factors</A>&#8221; beginning on page 9
of this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is April 15, 2026.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B></B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B><FONT ID="drs_001"></FONT>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 92%">&#160;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#drs_002">ABOUT THIS PROSPECTUS</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#drs_003">PROSPECTUS SUMMARY</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#drs_004">THE OFFERING</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#drs_005">CAUTIONARY STATEMENT ON FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#drs_006">RISK FACTORS</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#drs_007">THE TUMIM TRANSACTION</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#drs_008">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#drs_009">SELLING STOCKHOLDER</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#drs_010">PLAN OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#drs_011">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#drs_012">EXPERTS</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#drs_013">INTEREST OF NAMED EXPERTS AND COUNSEL</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#drs_014">DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#drs_015">INCORPORATION BY REFERENCE</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#drs_016">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Value: 1; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT ID="drs_002"></FONT>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus is part of a registration statement
that we have filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) pursuant to which the Selling Stockholder
may offer and sell, or otherwise dispose of, the shares of our common stock covered by this prospectus from time to time in one or more
transactions, as described in the section titled &#8220;<A HREF="#drs_010">Plan of Distribution</A>.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus provides you with a general description
of the securities that the Selling Stockholder may offer. We may add, update or change in a prospectus supplement any of the information
contained in this prospectus or the documents incorporated by reference. For further information about our business and our securities,
you should refer to the registration statement and the reports incorporated by reference in this prospectus, as described in &#8220;<A HREF="#drs_016">Where You Can Find Additional Information</A>&#8221; and &#8220;<A HREF="#drs_015">Incorporation of Certain Information by Reference</A>.&#8221; This prospectus contains
summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for
complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred
to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this
prospectus is a part, and you may obtain copies of those documents as described below under the heading &#8220;<A HREF="#drs_016">Where You Can Find Additional Information</A>.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You must not rely upon any information or representation
not contained or incorporated by reference in this prospectus. You should rely only on the information contained in this prospectus and
in any prospectus supplement (including in any documents incorporated by reference herein or therein). You should not assume that the
information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus
or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by
reference, even though this prospectus is delivered or securities are sold on a later date. Neither we, nor the Selling Stockholder, have
authorized any other person to provide you with different or additional information. Neither we, nor the Selling Stockholder, take responsibility
for, nor can we provide assurance as to the reliability of, any other information that others may provide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus may be used only in jurisdictions
where offers and sales of these securities are permitted. Except as otherwise set forth in this prospectus, neither we nor the Selling
Stockholder have taken any action to permit a public offering of these securities outside the United States or to permit the possession
or distribution of this prospectus outside the United States. Persons outside the United States who come into possession of this prospectus
must inform themselves about and observe any restrictions relating to the offering of these securities and the distribution of this prospectus
outside the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated, information contained
in this prospectus concerning our industry and the markets in which we operate, including our general expectations and market position,
market opportunity and market share, is based on information from our own management&#8217;s estimates and research, as well as from industry
and general publications and research, surveys and studies conducted by third parties. Management&#8217;s estimates are derived from publicly
available information, our knowledge of our industry and assumptions based on such information and knowledge, which we believe to be reasonable.
Our management&#8217;s estimates have not been verified by any independent source, and we have not independently verified any third-party
information. In addition, assumptions and estimates of our and our industry&#8217;s future performance are necessarily subject to a high
degree of uncertainty and risk due to a variety of factors, including those described in the section titled &#8220;<A HREF="#drs_006">Risk Factors</A>.&#8221;
These and other factors could cause our future performance to differ materially from our assumptions and estimates. See the sections titled
&#8220;<A HREF="#drs_006">Risk Factors</A>&#8221; and &#8220;<A HREF="#drs_005">Cautionary Statement on Forward-Looking Statements</A>.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We further note that the representations, warranties
and covenants made by us in any agreement that is filed as an exhibit to the registration statement of which this prospectus is a part
were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among
the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations,
warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should
not be relied on as accurately representing the current state of our affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tivic Health Systems, Inc., the Tivic logo and
other trademarks or service marks of Tivic appearing in this prospectus are the property of Tivic Health Systems, Inc. This prospectus
also includes trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks
and tradenames referred to in this prospectus appear without the &#174; and &#8482; symbols, but those references are not intended to indicate,
in any way, that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert
its rights, to these trademarks and tradenames.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT ID="drs_003"></FONT>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following summary highlights
information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making
your investment decision in our securities. Before investing in our securities, you should carefully read this prospectus, any
applicable prospectus supplement, and any documents incorporated by reference, including the information contained under the heading
&#8220;<A HREF="#drs_006">Risk Factors</A>&#8221; beginning on page 9 in this prospectus and under similar headings in our recent Annual Report on Form
10-K for the fiscal year ended December 31, 2025 or our Current Reports on Form 8-K following the most recent Annual Report on Form
10-K before making an investment decision.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Business Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tivic&#8482; Health Systems, Inc. (the &#8220;Company,&#8221;
&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Tivic,&#8221; or &#8220;Tivic Health&#8221;) is a late-stage biopharmaceutical
company whose lead program is Entolimod&#8482;. Entolimod is a recombinant TLR5 agonist with an extensive preclinical and clinical data
package supporting development as a medical countermeasure (MCM) for Acute Radiation Syndrome (ARS) and it subsyndromes, as well as for
adjunct therapy for oncology indications, such as neutropenia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During fiscal year 2025, Tivic executed a deliberate
and material strategic transformation: pivoting from a diversified bioelectronic medical device company to a focused biopharmaceutical
company built around the TLR5 agonist franchise. In addition to securing worldwide exclusive license rights and options to Entolimod and
its second-generation compound, Entolasta, in February 2025, Tivic established Velocity Bioworks&#8482; in December 2025 as subsidiary
contract development and manufacturing organization (CDMO) that is expected to support both Tivic and select third-party customers. At
the same time, Tivic exited the consumer healthtech business and suspended its prescription bioelectronic product development efforts
in order to focus resources fully on Entolimod development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is now focused on (1) advancing Entolimod
and its next generation compound Entolasta&#8482; through regulatory approval for acute radiation syndrome and into government procurement
and (2) expanding Entolimod&#8217;s designations into oncology-related conditions, including neutropenia, thrombocytopenia and general
and specific mucositis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Strategic Acquisition and the Biologics Program</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&#160;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A cornerstone of this transition was the execution
of an exclusive worldwide licensing agreement with Statera Biopharma, Inc. This agreement added Entolimod&#8482;, a late-stage Toll-like
Receptor 5 (TLR5) agonist, to our clinical pipeline. We further expanded this portfolio by exercising our option for an exclusive license
to the neutropenia indication for both Entolimod and our second-generation, immune-optimized candidate, Entolasta&#8482;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These assets represent a high-value investment
opportunity, having been the subject of over 40 clinical and preclinical trials supported by $140 million in prior capital, including
$35.6 million in non-dilutive funding from the Department of Defense (DoD), DTRA, NASA, and the NIH. The FDA has recognized the clinical
importance of Entolimod by granting it Fast Track and Orphan Drug designations for the prevention and treatment of Acute Radiation Syndrome
(ARS).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&#160;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Regulatory Pathway and Clinical Objectives</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&#160;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our immediate operational priority is the validation
of the manufacturing process required for the submission of a Biologics License Application (&#8220;BLA&#8221;) to the FDA. While the
BLA is our primary domestic objective, we are also exploring opportunities for the emergency use of Entolimod in select international
markets prior to formal U.S. commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beyond ARS, we are leveraging our active IND application
to initiate Phase 2 clinical studies targeting neutropenia and other oncology-related indications. Entolimod&#8217;s mechanism of action&#8212;activating
the NF-&#954;B pathway upstream of G-CSF&#8212;offers distinct therapeutic advantages. Clinical data (Krivokrysenko, et al., PLOS One,
2015) demonstrates that Entolimod not only stimulates hematopoiesis but also reduces apoptosis and accelerates tissue regeneration in
the gastrointestinal tract. We believe these anti-apoptotic and prophylactic properties position our TLR5 agonists as compelling alternatives
or adjunctive therapies to currently marketed G-CSF treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&#160;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&#160;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&#160;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&#160;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Divestment and Operational Realignment</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&#160;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To ensure the disciplined allocation of resources
toward our high-growth biologics program, the Board of Directors approved the wind-down of the ClearUP business and the cessation of active
research into non-invasive cervical vagus nerve stimulation (&#8220;ncVNS&#8221;). We expect the wind-down of the consumer business to
be substantially complete by year-end. In connection with this exit, the Company incurred approximately $347,000 in charges during 2025,
with an additional $20,000 to $50,000 expected to finalize the process. While we will generate minimal revenue during this transition,
we are retaining all intellectual property associated with our bioelectronic research for future monetization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&#160;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Launch of Velocity Bioworks (CDMO)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&#160;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2025, the Company launched Velocity
Bioworks, Inc., a wholly owned subsidiary operating as a CDMO. Velocity serves a dual strategic purpose: it de-risks our Entolimod commercialization
plan by providing internal control over the manufacturing and validation timeline, and it creates a new vertical revenue by offering specialized
services to external partners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Velocity offers biomanufacturing development work,
analytic support, and CGMP manufacturing capability.&#160; While we are in the early stages of market entry, this integrated model is
designed to drive operational efficiencies and provide a path toward diversified profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Reverse Stock Splits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Reverse Stock Split - 2025</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective March 7, 2025, the Company implemented
a reverse stock split of the Company&#8217;s issued and outstanding shares of common stock at a ratio of 1-for-17. As a result of the
reverse stock split, the total number of shares of common stock held by each stockholder of the Company was converted automatically into
the number of shares of common stock equal to the number of issued and outstanding shares of common stock held by each such stockholder
immediately prior to the reverse stock split divided by 17. No fractional shares were issued in connection with the reverse stock split,
and any fractional shares resulting from the reverse stock split were rounded up to the nearest whole share. Also, all options, warrants,
preferred stock and other convertible securities of the Company outstanding immediately prior to the reverse stock split were adjusted
in accordance with the terms of the plans, agreements or arrangements governing such options, warrants and other convertible securities.
There was no change to the par value, or authorized shares, of either the common stock or preferred stock, as a result of the reverse
stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Reverse Stock Split - 2023</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&#160;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective August 23, 2023, the Company implemented
a reverse stock split of the Company&#8217;s issued and outstanding shares of common stock at a ratio of 1-for-100. As a result of the
reverse stock split, the total number of shares of common stock held by each stockholder of the Company was converted automatically into
the number of shares of our common stock equal to the number of issued and outstanding shares of common stock held by each such stockholder
immediately prior to completion of the reverse stock split divided by 100. No fractional shares were issued in connection with the reverse
stock split, and any fractional shares resulting from the reverse stock split were rounded up to the nearest whole share. Also, all options,
warrants and other convertible securities of the Company outstanding immediately prior to the reverse stock split were adjusted in accordance
with the terms of the plans, agreements or arrangements governing such options, warrants and other convertible securities and subject
to rounding pursuant to such terms. There was no change to the par value, or authorized shares, of either the common stock or preferred
stock, as a result of the reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All share and per share amounts for our common
stock, as well as the number of shares of common stock issuable upon exercise of the options and warrants outstanding, and exercise prices
thereof, from dates prior to completion of the prior reverse stock splits that are included in this registration statement, including
the financial statements and footnotes thereto incorporated herein by reference, have been retroactively restated to give effect to the
reverse stock splits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><FONT ID="drs_018"></FONT>Implications of Being an Emerging Growth Company
and a Smaller Reporting Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an &#8220;emerging growth company&#8221;
as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. An emerging growth company may take advantage of specified
reduced reporting requirements that are otherwise generally applicable to public companies. As a result:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&#160;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are required to have only two years of audited financial statements and only two years of management&#8217;s discussion and analysis of financial condition and results of operation in this prospectus;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are not required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and financial statements (i.e., an auditor discussion and analysis) compliance with new or revised accounting standards until they are made applicable to private companies;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are not required to engage an auditor to provide an attestation to report on our internal control over financial reporting pursuant to Section&#160;404(b)&#160;of the Sarbanes-Oxley Act of 2002;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are not required to comply with certain disclosure requirements related to executive compensation, such as the requirement to disclose the correlation between executive compensation and performance and the requirement to present a comparison of our Chief Executive Officer&#8217;s compensation to our median employee compensation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are not required to submit certain executive compensation matters to stockholder advisory votes, such as &#8220;say on pay,&#8221; &#8220;say on frequency&#8221; and &#8220;say on golden parachute arrangements.&#8221;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may take advantage of these reduced reporting
and other requirements until the earlier of (i)&#160;the last day of the first fiscal year following the fifth anniversary of the completion
of this offering; (ii)&#160;the last day of the first fiscal year in which we have total annual gross revenue of at least $1.07 billion;
(iii)&#160;the last day of the fiscal year in which we are deemed to be a &#8220;large accelerated filer&#8221; as defined in Rule&#160;12b-2
under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), which would occur if the market value of our common
stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such fiscal year; or
(iv)&#160;the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have elected to take advantage of certain of
the reduced disclosure obligations in this prospectus and the registration statement of which this prospectus is a part, and we may elect
to take advantage of other reduced reporting requirements in the future. As a result, the information that we provide to our stockholders
may be different than, and not comparable to, information presented by other public reporting companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also a &#8220;smaller reporting company&#8221;
as defined in the Exchange Act and have elected to take advantage of certain of the scaled disclosures available to smaller reporting
companies. We may be a smaller reporting company even after we are no longer an emerging growth company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company was incorporated in California in
September 2016 and reincorporated as a Delaware corporation in June 2021. Our principal executive offices are located at 1305 E. Houston
St., Building 1, Suite 311, San Antonio, Texas 78205. Our telephone number is (888) 276-6888. Our website address is www.tivichealth.com.
Information contained on, or that can be accessible through, our website is not a part of this prospectus and the inclusion of our website
address in this prospectus is an inactive textual reference only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Associated with this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business and our ability to implement our
business strategy are subject to numerous risks, as more fully described in the section of this prospectus titled &#8220;<A HREF="#drs_006">Risk Factors</A>&#8221;
and under similarly titled headings of the documents incorporated herein by reference. You should read these risks before you invest in
our securities. We may be unable, for many reasons, including those that are beyond our control, to implement our business strategy. In
particular, risks associated with this offering include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&#160;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&#160;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It is not possible to predict the actual number of shares we will sell to Tumim under the Purchase Agreement, or the actual gross proceeds resulting from those sales.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The terms of the Purchase Agreement limit the amount of shares we may issue to Tumim, which may limit our ability to utilize the arrangement to enhance our cash resources.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors who buy shares at different times will likely pay different prices.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The issuance of common stock to Tumim may cause substantial dilution to our existing stockholders, and the sale of such shares acquired by Tumim could cause the price of our common stock to decline.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our management will have broad discretion over the use of the net proceeds from our sale of shares of common stock to Tumim pursuant to the Purchase Agreement, if any, and you may not agree with how we use the proceeds, and the proceeds may not be invested successfully.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You may experience additional dilution as a result of future equity offerings.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Tumim Transaction</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On February 6, 2026,
we entered into the Purchase Agreement with Tumim, pursuant to which, upon effectiveness of the registration statement that includes this
prospectus, we will have the right, but not the obligation, to sell to Tumim, and Tumim will have the obligation to purchase from us,
up to $50.0 million (the &#8220;ELOC Value&#8221;) of shares of our common stock (the &#8220;Put Shares&#8221;), from time to time over
the 24-month term of the Purchase Agreement, subject to certain conditions precedent and other limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Unless earlier terminated,
the Purchase Agreement will remain in effect until the earliest of: (a) the first day of the calendar month immediately following the
24-month anniversary of the Effective Date (as defined in the Purchase Agreement); (b) the date on which Tumim has purchased an aggregate
number of shares of common stock equal to the ELOC Value; (c) the date on which our common stock shall have failed to be listed or quoted
on the Nasdaq Capital Market or other nationally recognized securities exchange; and (d) the date on which the Company is subject to a
bankruptcy pursuant to applicable bankruptcy laws (such period, the &#8220;Commitment Period&#8221;). We have the right to terminate the
Purchase Agreement at any time, subject to the limitations set forth in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">During the Commitment
Period, we will have the right, but not the obligation, to direct Tumim to purchase the Put Shares by delivering written notice to Tumim
(a &#8220;Put Notice&#8221;) on any trading day to purchase a number of Put Shares pursuant to a formula set forth in the Purchase Agreement.
If we elect to use a one-day valuation period in the Put Notice (the &#8220;One-Day Valuation Period&#8221;), the purchase price for the
Put Shares under the Purchase Agreement will be equal to 97% of the volume-weighted average price (&#8220;VWAP&#8221;) of our common stock
on any trading day during such One-Day Valuation Period, subject to adjustment as provided in the Purchase Agreement, following receipt
of the Put Shares by Tumim. If we elect to use a One-Day Valuation Period to determine the VWAP Purchase Price in the Put Notice, such
Put Notice shall direct Tumim to purchase Put Shares in an amount not to exceed the lesser of (i) 15% of the daily trading volume of the
common stock on the VWAP Purchase Exercise Date (as defined in the Purchase Agreement), or (ii) the quotient (rounded to the nearest whole
number) obtained by dividing (x) $1,000,000 by (y) the VWAP on the VWAP Purchase Exercise Date (in each case to be appropriately adjusted
for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction during the
applicable period) (the &#8220;One-Day Maximum Amount&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If we elect to use a
three-day valuation period in the Put Notice (the &#8220;Three-Day Valuation Period&#8221;), the purchase price for the Put Shares under
the Purchase Agreement will be equal to 95% of the lowest daily VWAP of our common stock on any trading day during such Three-Day Valuation
Period, subject to adjustment as provided in the Purchase Agreement, following receipt of the Put Shares by Tumim. If we elect to use
a Three-Day Valuation Period to determine the VWAP Purchase Price in the Put Notice, such Put Notice shall direct Tumim to purchase Put
Shares in an amount not to exceed the lesser of (i) 40% of the daily trading volume of the common stock on the VWAP Purchase Exercise
Date, or (ii) the quotient (rounded to the nearest whole number) obtained by dividing (x) $2,500,000 by (y) the VWAP on the VWAP Purchase
Exercise Date (in each case to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse
stock split or other similar transaction during the applicable period (the &#8220;Three-Day Maximum Amount&#8221; and, together with the
One-Day Maximum Amount, the &#8220;Maximum Amounts&#8221; and, each, a &#8220;Maximum Amount&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In addition to the applicable
Maximum Amount limitations, Tumim&#8217;s obligation to purchase Put Shares is subject to a 4.99% beneficial ownership blocker (which
may be increased to 9.99% at the election of Tumim). On February 20, 2026, Tumim elected to increase the beneficial ownership limitation
from 4.99% to 9.99% to be effective April 21, 2026. Additionally, pursuant to the Purchase Agreement, we may not sell or issue to Tumim
more than&#160;506,848&#160;shares of our common stock, representing 19.99% of the number of shares of our common stock issued and outstanding
immediately prior to execution of the Purchase Agreement (such maximum number of shares, the &#8220;Exchange Cap&#8221;), unless and until
we obtain stockholder approval to issue additional shares, in accordance with applicable Nasdaq rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Actual sales of shares
of our common stock, if any, to Tumim under the Purchase Agreement will depend on a variety of factors to be determined by us from time
to time, including, among others, market conditions, the trading price of our common stock and determinations by us as to the appropriate
sources of funding for the Company and our operations. The net proceeds to the Company from sales of our common stock to Tumim under the
Purchase Agreement, if any, will depend on the frequency and prices at which we sell shares to Tumim under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As consideration for
Tumim&#8217;s commitment to purchase shares of our common stock under the Purchase Agreement, we issued Tumim a pre-funded warrant to
purchase 437,012 shares of common stock (the &#8220;Commitment Pre-Funded Warrant&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with the
Purchase Agreement, we entered into a registration rights agreement with Tumim (the &#8220;Registration Rights Agreement&#8221;), pursuant
to which we agreed to register for resale under the Securities Act the shares of our common stock that may be issued to Tumim under the
Purchase Agreement, including the shares of common stock underlying the Commitment Pre-Funded Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Purchase Agreement and Registration Rights
Agreement contain customary representations, warranties, covenants and agreements, as well as customary conditions to Tumim&#8217;s obligation
to purchase the Put Shares. The representations, warranties and covenants contained in such agreements were made only for purposes of
such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations
agreed upon by the contracting parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not know what the purchase price for our
common stock will be, and therefore cannot be certain as to the number of shares we might issue to Tumim under the Purchase Agreement
after the date of this prospectus. As of February 5, 2026, immediately prior to execution of the Purchase Agreement and issuance of the
Commitment Pre-Funded Warrant to Tumim, there were 2,535,509 shares of our common stock outstanding. Although the Purchase Agreement provides
that we may sell up to an aggregate of $50.0 million of shares of our common stock to Tumim, only 956,222 shares of our common stock are
being registered for resale under this prospectus, which represents (i)&#160;519,210&#160;shares of our common stock that we may issue
and sell to Tumim in the future under the Purchase Agreement, if and when we elect to sell shares of our common stock to Tumim under the
Purchase Agreement, and (ii) the 437,012&#160;shares of common stock issuable to Tumim upon exercise of the Commitment Pre-Funded Warrant.
Depending on the market prices of our common stock at the time we elect to issue and sell shares of our common stock to Tumim under the
Purchase Agreement, we may need to register for resale under the Securities Act additional shares of our common stock in order to receive
aggregate gross proceeds equal to the $50.0 million total commitment available to us under the Purchase Agreement. If all of such 956,222
shares of our common stock offered hereby were issued and outstanding as of the date of this prospectus, such shares would represent approximately
24.94% of the total number of outstanding shares of common stock. If we elect to issue and sell to Tumim under the Purchase Agreement
more than the 956,222 shares of our common stock (other than shares of common stock issuable to Tumim upon exercise of the Commitment
Pre-Funded Warrant) being registered for resale by Tumim under this prospectus (assuming we have the right to do so under Nasdaq rules),
which we have the right, but not the obligation, to do, we must first register for resale under the Securities Act any such additional
shares of our common stock, which could cause additional substantial dilution to our stockholders. The number of shares of our common
stock ultimately offered for sale by Tumim is dependent upon the number of shares we sell to Tumim under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Issuances of our common stock to Tumim under the
Purchase Agreement will not affect the rights or privileges of our existing stockholders, except insofar as the economic and voting interests
of each of our existing stockholders are diluted as a result of any such issuance. Although the number of shares of our common stock that
our existing stockholders own will not decrease, the shares of our common stock owned by our existing stockholders will represent a smaller
percentage of the total outstanding shares of our common stock after any such issuance of shares of our common stock to Tumim under the
Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT ID="drs_004"></FONT>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares offered by the Selling Stockholder </B></FONT></TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="text-align: justify; width: 59%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to an aggregate of 956,222 shares of our common stock, consisting of (i) 519,210 shares of common stock that we may sell to Tumim pursuant to the Purchase Agreement from time to time after the registration statement that includes this prospectus is declared effective; and (ii) 437,012 shares of common stock issuable upon exercise of the Commitment Pre-Funded Warrant.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common stock outstanding prior to this offering</B></FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,877,926 shares of common stock.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common stock to be outstanding after this offering</B></FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,834,148 shares of common
    stock.<SUP>(1)</SUP></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of proceeds</B></FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Selling Stockholder will receive all of the proceeds from the sale of the shares offered for sale by it under this prospectus. We will not receive proceeds from the sale of the shares by the Selling Stockholder. However, we will receive proceeds from the sales, if any, of shares of our common stock to the Selling Stockholder under the Purchase Agreement. We cannot predict the number or value of the shares that we will sell to the Selling Stockholder pursuant to the Purchase Agreement. Any proceeds we receive are expected to be used for general corporate purposes, including operating expenses, capital expenditures and working capital. See &#8220;<A HREF="#drs_008">Use of Proceeds</A>.&#8221;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk factors</B></FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment in our securities involves a high degree of risk and could result in a loss of your entire investment. You should read the section titled &#8220;<A HREF="#drs_006">Risk Factors</A>&#8221; beginning on page 9 of this prospectus and the other information included or incorporated by reference into this prospectus for a discussion of factors to consider carefully before deciding to invest in our securities.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market symbol and trading</B></FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our common stock is listed on the Nasdaq Capital Market under the ticker symbol &#8220;TIVC.&#8221; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><SUP>(1)</SUP>&#160;&#160;&#160;Except
as otherwise indicated herein, the number of shares of our common stock to be outstanding after this offering is based on 2,877,926 shares
of common stock outstanding as of April 8, 2026, which excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&#160;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">392,494 shares of common stock issuable upon exercise of outstanding options to purchase shares of common stock outstanding, with a weighted-average exercise price of approximately $8.00 per share;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,513,550 shares of common stock issuable upon exercise of outstanding warrants to purchase shares of common stock, with a weighted-average exercise price of approximately $3.12 per share;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39,981 shares of common stock issuable upon settlement of outstanding restricted stock units;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">237, 200 shares of common stock issuable
    upon conversion of outstanding shares of our Series A Non-Voting Convertible Preferred Stock;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> 2,748,549 shares of common stock issuable
    upon conversion of outstanding shares of our Series B Non-Voting Convertible Preferred Stock;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,996,347 shares of common stock issuable upon conversion of outstanding shares of our Series C Non-Voting Convertible Preferred Stock; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">219,566 shares of common stock reserved for future issuance under our amended and restated 2021 Equity Incentive Plan (the &#8220;A&amp;R 2021 Plan&#8221;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT ID="drs_005"></FONT>CAUTIONARY STATEMENT ON FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This prospectus and the
documents incorporated by reference contain &#8220;forward-looking&#8221; statements, as such term is defined by the Commission in its
rules, regulations and releases, which represent our expectations or beliefs, including but not limited to, statements concerning our
operations, economic performance, financial condition, growth and acquisition strategies, investments, and future operational plans. For
this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements.
Without limiting the generality of the foregoing, words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221;
&#8220;anticipate,&#8221; &#8220;intent,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221;
&#8220;predict&#8221; or &#8220;continue&#8221; or the negative or other variations thereof or comparable terminology are intended to
identify forward-looking statements. These statements, by their nature, involve substantial risks and uncertainties, certain of which
are beyond our control, and actual results may differ materially depending on a variety of important factors, including uncertainty related
to acquisitions, governmental regulation, managing and maintaining growth, the operations of the Company, volatility of stock price, commercial
viability of our product candidates and any other factors discussed in this and other registrant filings with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These risks and uncertainties and other factors
include, but are not limited to those set forth under &#8220;<A HREF="#drs_006">Risk Factors</A>&#8221; of this prospectus. Given these risks and uncertainties,
readers are cautioned not to place undue reliance on our forward-looking statements. All subsequent written and oral forward-looking statements
attributable to us or to persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Except
as otherwise required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements or the
risk factors described in this prospectus or in the documents we incorporate by reference, whether as a result of new information, future
events, changed circumstances or any other reason after the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus contains forward-looking statements,
including statements regarding, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&#160;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our anticipated needs for working capital;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to secure additional financing;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to continue as a going concern;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to sell shares of our common stock to Tumim pursuant to the terms of the Purchase Agreement, and in accordance with applicable Nasdaq rules, and our ability to register and maintain the registration of the shares issued and issuable thereunder;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our business plans and strategies, including our product development efforts;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory or legal developments in the United States and other countries;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the level of expenses related to our product development and operations;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our efforts to expand our products and our business; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to maintain compliance with the listing requirements of the Nasdaq Capital Market.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Actual events or results may differ materially
from those discussed in forward-looking statements as a result of various factors, including, without limitation, the risks outlined under
the section of this prospectus titled &#8220;<A HREF="#drs_006">Risk Factors</A>&#8221; and matters described in prospectus generally. In light of these risks
and uncertainties, there can be no assurance that the forward-looking statements contained in this prospectus will in fact occur. We caution
you not to place undue reliance on these forward-looking statements. In addition to the information expressly required to be included
in this prospectus, we will provide such further material information, if any, as may be necessary to make the required statements, in
light of the circumstances under which they are made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#160;</B></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><BR>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT ID="drs_006"></FONT>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Investing in our securities involves a high
degree of risk. You should carefully consider the risks described below, as well as those described under &#8220;Risk Factors&#8221; contained
in our most recent Annual Report on Form 10-K, and in our updates to those Risk Factors included in our Quarterly Reports on Form 10-Q
or Current Reports on Form 8-K following the most recent Annual Report on Form 10-K, and in all other information appearing in this prospectus
or incorporated by reference into this prospectus and any applicable prospectus supplement, before deciding whether to invest in our securities.
The occurrence of any of the events or developments described below and in our filings with the Commission could harm our business, financial
condition, operating results, and/or growth prospects.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&#160;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The risks described below and in our filings
with the Commission are not the only ones facing us. Our business is also subject to the risks that affect many other companies, such
as competition, labor relations, general economic conditions, inflation, supply chain constraints, geopolitical changes, and international
operations. We operate in a rapidly changing environment that involves a number of risks, some of which are beyond our control. Additional
risks not currently known to us or that we currently believe are immaterial also may impair our business operations and our liquidity.
The risks described below and in our filings with the Commission could cause our actual results to differ materially from those contained
in the forward-looking statements we have made in this prospectus, the information incorporated herein by reference, and those forward-looking
statements we may make from time to time. You should understand that it is not possible to predict or identify all such factors. This
prospectus is qualified in its entirety by these risk factors.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>It is not possible to predict the actual
number of shares we will sell to Tumim under the Purchase Agreement, if any, or the actual gross proceeds resulting from those sales.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tumim has committed to purchase up to $50.0 million
of shares of our common stock, subject to certain limitations and conditions set forth in the Purchase Agreement. The shares of our common
stock that may be issued under the Purchase Agreement may be sold by us to Tumim at our discretion from time to time throughout the term
of the agreement. We generally have the right to control the timing and amount of any sales of our shares of common stock to Tumim under
the Purchase Agreement. Sales of our common stock, if any, to Tumim under the Purchase Agreement will depend upon market conditions and
other factors to be determined by us. We may ultimately decide to sell to Tumim all, some or none of the shares of our common stock that
may be available for us to sell to Tumim pursuant to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because the per share purchase price that Tumim
will pay for shares of our common stock in any transaction that we may elect to effect pursuant to the Purchase Agreement will be equal
to (i) 97% of the lowest VWAP of our common stock on the one trading day during a One-Day Valuation Period, or (ii) 95% of the lowest
VWAP of our common stock on any trading day during a Three-Day Valuation Period, immediately after receipt of the Put Shares by Tumim
(subject to adjustment as provided in the Purchase Agreement), as of the date of this prospectus, it is not possible for us to predict
the number of shares of common stock that we will sell to Tumim under the Purchase Agreement, the purchase price per share that Tumim
will pay for shares purchased from us under the Purchase Agreement, or the aggregate gross proceeds that we will receive from those purchases
by Tumim under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, although the Purchase Agreement
provides that we may sell up to an aggregate of $50.0 million of shares of our common stock to Tumim, only 956,222 shares of our common
stock issuable pursuant to the Purchase Agreement are being registered under the Securities Act for resale by Tumim under the registration
statement that includes this prospectus. In order to utilize the full value of the Purchase Agreement, we must first obtain stockholder
approval to issue shares of common stock in excess of the Exchange Cap under the Purchase Agreement in accordance with applicable Nasdaq
rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If it becomes necessary for us to issue and sell
to Tumim under the Purchase Agreement more than the 956,222 shares of our common stock being registered for resale by Tumim under the
registration statement that includes this prospectus in order to receive aggregate gross proceeds equal to $50.0 million under the Purchase
Agreement, we must first file with the Commission one or more additional registration statements to register any such additional shares
of our common stock we wish to sell to Tumim from time to time under the Purchase Agreement, which the Commission must declare effective,
in each case before we may elect to sell any additional shares of our common stock to Tumim under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The terms of the Purchase Agreement limit
the amount of shares we may issue to Tumim, which may limit our ability to utilize the arrangement to enhance our cash resources.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Purchase Agreement includes restrictions on
our ability to sell shares of our common stock to Tumim, including the Exchange Cap, and, subject to specified limitations, if a sale
would cause Tumim to beneficially own more than 4.99% (which may be increased to 9.99% at the election of Tumim) of our issued and outstanding
shares of common stock. On February 20, 2026, Tumim elected to increase the beneficial ownership limitation from 4.99% to 9.99% to be
effective April 21, 2026. Accordingly, we cannot guarantee that we will be able to sell the full number of shares that Tumim has committed
to purchase, or any shares at all. If we cannot sell the full amount of shares that Tumim has committed to purchase because of these limitations,
we may be required to utilize more costly and time-consuming means of accessing the capital markets, which could materially adversely
affect our liquidity and cash position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Investors who buy shares at different times
will likely pay different prices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will have discretion, subject to market demand,
to vary the timing, prices, and numbers of shares sold to Tumim pursuant to the Purchase Agreement. If and when we do elect to sell shares
of our common stock to Tumim pursuant to the Purchase Agreement, after Tumim has acquired such shares, Tumim may resell all, some or none
of such shares at any time, or from time to time, in its discretion and at different prices. As a result, investors who purchase shares
from Tumim in this offering at different times will likely pay different prices for those shares, and so may experience different levels
of dilution, and in some cases substantial dilution, and different outcomes in their investment results. Investors may experience a decline
in the value of the shares they purchase from Tumim in this offering as a result of future sales made by Tumim to purchasers or by us
to Tumim at prices lower than the prices such investors paid for their shares in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The issuance of common stock to Tumim may
cause substantial dilution to our existing stockholders, and the sale of such shares acquired by Tumim could cause the price of our common
stock to decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are registering for resale by Tumim 956,222
shares of our common stock, consisting of 519,210 shares that we may issue and sell to Tumim under the Purchase Agreement and an additional
437,012 shares of common stock issuable to Tumim upon exercise of the Commitment Pre-Funded Warrant. If Tumim sells, or the market perceives
that Tumim intends to sell, a substantial number of shares of our common stock in the public market, the price of our common stock may
decline. The shares of common stock offered under this prospectus represent a significant number of shares in comparison to the number
of shares of our common stock currently outstanding, and if sold in the market all at once or at approximately the same time, could depress
the market price of our common stock. Additionally, such conditions may make it more difficult for us to sell equity or equity-related
securities in the future at a time and price that we deem reasonable or appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our management will have broad discretion
over the use of the net proceeds from our sale of shares of common stock to Tumim pursuant to the Purchase Agreement, if any, and you
may not agree with how we use the proceeds, and the proceeds may not be invested successfully.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not selling any shares of our common stock
under this prospectus and will not receive any of the proceeds from the sale of shares of our common stock by Tumim. However, we will
receive proceeds from the sales, if any, of shares of our common stock to Tumim under the Purchase Agreement. Our management will have
broad discretion as to the use of the net proceeds from our sale of shares of common stock to Tumim pursuant to the Purchase Agreement,
and we could use them for purposes other than those contemplated at the time of commencement of this offering. Accordingly, you will be
relying on the judgment of our management with regard to the use of those net proceeds, and you will not have the opportunity, as part
of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that, pending their use, we may
invest those net proceeds in a way that does not yield a favorable, or any, return for us. The failure of our management to use such funds
effectively could have a material adverse effect on our business, financial condition, operating results and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You may experience additional dilution as
a result of future equity offerings</I>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to raise additional capital, we may sell
additional shares of our common stock or other securities convertible into or exchangeable for our common stock. The price per share at
which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions
may be lower than the price per share that you purchase the shares of common stock being offered hereunder by the selling stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT ID="drs_007"></FONT>THE TUMIM TRANSACTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following provides a summary of the Purchase
Agreement entered into with the Selling Stockholder pursuant to which it may in the future purchase from us the shares of our common stock
being registered hereby for resale by the Selling Stockholder. The following summary of such transactions does not purport to be complete
and is subject to, and qualified in its entirety by reference to, the forms of transaction documents entered into in connection with such
transaction, which are filed as exhibits to the registration statement of which this prospectus is a part and which are incorporated herein
by reference. You should carefully read this entire prospectus, including the information incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 6, 2026, we entered into the Purchase
Agreement with Tumim, pursuant to which, upon effectiveness of the registration statement that includes this prospectus, we will have
the right, but not the obligation, to sell to Tumim, and Tumim will have the obligation to purchase from us, up to the applicable Maximum
Amount of Put Shares from time to time over the term of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless earlier terminated, the Purchase Agreement
will remain in effect during the Commitment Period. We have the right to terminate the Purchase Agreement at any time, subject to the
limitations set forth in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the Commitment Period, we will have the
right, but not the obligation, to direct Tumim to purchase the Put Shares by delivering a Put Notice on any trading day to purchase a
number of Put Shares pursuant to a formula set forth in the Purchase Agreement. If we elect to use a One-Day Valuation Period in the Put
Notice, the purchase price for the Put Shares will be equal to 97% of the VWAP of our common stock on any trading day during such One-Day
Valuation Period, subject to adjustment as provided in the Purchase Agreement, following receipt of the Put Shares by Tumim. If we elect
to use a One-Day Valuation Period to determine the VWAP Purchase Price in the Put Notice, such Put Notice shall direct Tumim to purchase
Put Shares in an amount not to exceed the One-Day Maximum Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we elect to use a Three-Day Valuation Period
in the Put Notice, the purchase price for the Put Shares under the Purchase Agreement will be equal to 95% of the lowest daily VWAP of
our common stock on any trading day during such Three-Day Valuation Period, subject to adjustment as provided in the Purchase Agreement,
following receipt of the Put Shares by Tumim. If we elect to use a Three-Day Valuation Period to determine the VWAP Purchase Price in
the Put Notice, such Put Notice shall direct Tumim to purchase Put Shares in an amount not to exceed the Three-Day Maximum Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the applicable Maximum Amount limitations,
Tumim&#8217;s obligation to purchase Put Shares is subject to a 4.99% beneficial ownership blocker (which may be increased to 9.99% at
the election of Tumim). On February 20, 2026, Tumim elected to increase the beneficial ownership limitation from 4.99% to 9.99% to be
effective April 21, 2026. Additionally, pursuant to the Purchase Agreement, we may not sell or issue to Tumim more than&#160;506,848&#160;shares
of our common stock, representing the maximum number of shares that may be issued under the Exchange Cap, unless and until we obtain stockholder
approval to issue additional shares, in accordance with applicable Nasdaq rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Actual sales of shares
of our common stock, if any, to Tumim under the Purchase Agreement will depend on a variety of factors to be determined by us from time
to time, including, among others, market conditions, the trading price of our common stock and determinations by us as to the appropriate
sources of funding for the Company and our operations. The net proceeds to the Company from sales of our common stock to Tumim under the
Purchase Agreement, if any, will depend on the frequency and prices at which we sell shares to Tumim under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As consideration for Tumim&#8217;s commitment
to purchase shares of our common stock under the Purchase Agreement, we issued Tumim the Commitment Pre-Funded Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Purchase Agreement contains certain representations,
warranties, covenants and events of default. There are no restrictions on future financings, rights of first refusal, participation rights,
penalties or liquidated damages in the Purchase Agreement or Registration Rights Agreement, except we are prohibited (with certain specified
exceptions) from effecting or entering into an &#8220;equity line of credit&#8221; or substantially similar transaction or a variable
rate transaction during the term of the Purchase Agreement without the prior written consent of Tumim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have the right to terminate the Purchase Agreement
at any time, at no cost or penalty, upon written notice to Tumim except during any time that Tumim holds any shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Registration Rights Agreement,
we agreed to use our reasonable best efforts to cause the registration statement of which this prospectus constitutes a part to become
effective and to remain continuously effective until the earlier of: (i) the date on which Tumim shall have sold all of the Shares and
(ii) the date of termination of the Purchase Agreement if, as of such termination date, Tumim holds no Shares (or, if applicable, the
date on which such securities cease to be registrable after the date of termination of the Purchase Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additional information with respect to the Purchase
Agreement, the Shares, and the Registration Rights Agreement is contained in this prospectus under the heading &#8220;<A HREF="#drs_009">Selling Stockholder</A>&#8221;
and in our Current Report on Form 8-K filed with the Securities and Exchange Commission on February 9, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Effect of Performance of the Purchase Agreement
on our Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of February 5, 2026, immediately prior to execution
of the Purchase Agreement and issuance of the Commitment Pre-Funded Warrant to Tumim, there were 2,535,509 shares of our common stock
outstanding. Although the Purchase Agreement provides that we may sell up to an aggregate of $50.0 million of shares of our common stock
to Tumim, only 956,222 shares of our common stock are being registered for resale under this prospectus, which represents (i) 519,210
shares of our common stock that we may issue and sell to Tumim in the future under the Purchase Agreement, if and when we elect to sell
shares of our common stock to Tumim under the Purchase Agreement, and (ii) 437,012 shares of common stock issuable upon exercise of the
Commitment Pre-Funded Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not know what the Purchase Price for our
common stock will be or whether there will occur an exception to the Exchange Cap, and therefore cannot be certain as to the number of
shares we might sell and issue to Tumim under the Purchase Agreement after the date of this prospectus. Depending on the market prices
of our common stock at the time we elect to issue and sell shares of our common stock to Tumim under the Purchase Agreement, and assuming
we receive stockholder approval to remove the Exchange Cap, we may need to register for resale under the Securities Act additional shares
of our common stock in order to receive aggregate gross proceeds equal to the $50.0 million total commitment available to us under the
Purchase Agreement. If all of 956,222 shares of our common stock offered hereby were issued and outstanding as of the date of this prospectus,
such shares would represent approximately 24.94% of the total number of outstanding shares of our common stock. If we elect to issue and
sell to Tumim under the Purchase Agreement more than 956,222 shares of our common stock (other than shares of common stock issuable upon
exercise of the Commitment Pre-Funded Warrant) being registered for resale by Tumim under this prospectus (assuming we have the right
to do so under Nasdaq rules), which we have the right, but not the obligation, to do, we must first register for resale under the Securities
Act any such additional shares of our common stock, which could cause additional substantial dilution to our stockholders. The number
of shares of our common stock ultimately offered for sale by Tumim will be dependent upon the number of shares we sell to Tumim under
the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Issuances of our common stock to Tumim under the
Purchase Agreement will not affect the rights or privileges of our existing stockholders, except that the economic and voting interests
of each of our existing stockholders will be diluted as a result of any such issuance. Although the number of shares of our common stock
that our existing stockholders own will not decrease, the shares of our common stock owned by our existing stockholders will represent
a smaller percentage of the total outstanding shares of our common stock after any such issuance of shares of our common stock to Tumim
under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT ID="drs_008"></FONT>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 184.9pt; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholder will receive all of the
proceeds from the sale of the shares offered for sale by it under this prospectus. We will not receive proceeds from the sale of the shares
by the Selling Stockholder. However, we will receive proceeds from the sales, if any, of shares of our common stock to the Selling Stockholder
under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot predict the number or value of the shares
that we will sell to the Selling Stockholder pursuant to the Purchase Agreement. We currently intend to use any proceeds that we receive
from the sales of shares to the Selling Stockholder pursuant to the Purchase Agreement for general corporate purposes, including operating
expenses, capital expenditures and working capital. We have broad discretion in determining how the proceeds we receive, if any, will
be used, and our discretion is not limited by the aforementioned possible uses. As we are unable to predict the timing or amount of potential
issuances of the shares of our common stock issuable pursuant to the Purchase Agreement, we cannot specify with certainty all of the particular
uses for the net proceeds that we will have from the sale of such shares. We may use the proceeds for purposes that are not contemplated
at the time of this offering. It is possible that no shares will be issued under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will incur all costs associated with this prospectus
and the registration statement of which it is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B><FONT ID="drs_009"></FONT>SELLING
STOCKHOLDER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus relates to the resale from time
to time by Tumim of any or all of the shares of common stock that have been and may be issued by us to Tumim under the Purchase Agreement.
For additional information regarding the issuance of our common stock covered by this prospectus, see the section titled &#8220;<A HREF="#drs_007"><I>The
Tumim Transaction</I></A>&#8221; above. We are registering the shares of common stock included in this prospectus pursuant to the provisions
of the Registration Rights Agreement to permit the Selling Stockholder to offer the Shares included in this prospectus for resale from
time to time. Except as set forth in the Purchase Agreement, the Registration Rights Agreement, and in Item 15, &#8220;Recent
Sales of Unregistered Securities&#8221; of the registration statement of which this prospectus forms a part, Tumim has not had any
material relationship with us within the past three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below presents information regarding
the Selling Stockholder and the Shares that may be resold by the Selling Stockholder from time to time under this prospectus. This table
is prepared based on information supplied to us by the Selling Stockholder, and reflects holdings as of April 8, 2026. The number of shares
in the column &#8220;Maximum Number of Shares of Common Stock to be Offered Pursuant to this Prospectus&#8221;
represents all of the Shares being offered for resale by the Selling Stockholder under this prospectus. The Selling Stockholder may sell
some, all, or none of the Shares being offered for resale in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not know how long the Selling Stockholder
will hold the Shares before selling them or whether they will sell them at all, and, except as set forth in the section titled &#8220;<A HREF="#drs_010"><I>Plan
of Distribution</I></A>&#8221; in this prospectus, we are not currently aware of any existing agreements, arrangements or understandings
between the Selling Stockholder and any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of
the shares of our common stock being offered for resale by this prospectus by the Selling Stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beneficial ownership is determined in accordance
with Rule 13d-3(d) promulgated by the Commission under the Exchange Act, and includes shares of common stock with respect to which the
Selling Stockholder has sole or shared voting and investment power. The percentage of shares of common stock beneficially owned by the
Selling Stockholder prior to the offering shown in the table below is based on an aggregate of 2,877,926 shares of our common stock outstanding
on April 8, 2026. Because the purchase price of the Shares of common stock issuable under the Purchase Agreement is determined on each
VWAP Purchase Date, with respect to a VWAP Purchase (as defined in the Purchase Agreement), the number of Shares that may actually be
sold by the Company under the Purchase Agreement may be fewer than the number of Shares being offered for resale by this prospectus. The
fourth column assumes the sale of all of the Shares offered for resale by the Selling Stockholder pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&#160;</TD>
    <TD>&#160;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number of Shares of Common Stock Owned Prior to this Offering</B></FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Maximum Number of Shares of Common Stock to be Offered Pursuant to this </B></FONT></TD>
    <TD>&#160;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Maximum Number of Shares of Common Stock Owned After this Offering</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name of Selling Stockholder</B></FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number<SUP>(1)</SUP></B></FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percent<SUP>(2)</SUP></B></FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Prospectus</B></FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number<SUP>(3)</SUP></B></FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percent<SUP>(2)</SUP></B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #EEEEEE">
    <TD STYLE="width: 33%"><FONT STYLE="font-size: 10pt">Tumim Stone Capital, LLC<SUP>(4)</SUP></FONT></TD>
    <TD STYLE="width: 2%">&#160;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">437,012</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 10pt"><SUP>(5)</SUP></FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="width: 2%">&#160;</TD>
    <TD STYLE="width: 13%; text-align: right"><FONT STYLE="font-size: 10pt">956,222</FONT></TD>
    <TD STYLE="width: 2%">&#160;</TD>
    <TD STYLE="width: 13%; text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD STYLE="width: 2%">&#160;</TD>
    <TD STYLE="width: 13%; text-align: right"><FONT STYLE="font-size: 10pt">0%</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Represents less than 1.0%.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with Rule 13d-3(d) under the Exchange Act, we have excluded from the number of shares beneficially owned prior to the offering all of the shares that Tumim may be required to purchase under the Purchase Agreement, because the issuance of such shares is solely at our discretion and is subject to conditions contained in the Purchase Agreement, the satisfaction of which are entirely outside of Tumim&#8217;s control, including the registration statement that includes this prospectus becoming and remaining effective. Furthermore, the VWAP Purchases of common stock are subject to certain agreed upon maximum amount limitations set forth in the Purchase Agreement. Also, the Purchase Agreement prohibits us from issuing and selling any shares of our common stock to Tumim to the extent such shares, when aggregated with all other shares of our common stock then beneficially owned by Tumim, would cause Tumim&#8217;s beneficial ownership of our common stock to exceed 4.99% (which may be increased to 9.99% at the election of Tumim). On February 20, 2026, Tumim elected to increase the beneficial ownership limitation from 4.99% to 9.99% to be effective April 21, 2026. The Purchase Agreement also prohibits us from issuing or selling shares of our common stock under the Purchase Agreement in excess of a 19.99% exchange cap unless we obtain stockholder approval to do so, or unless sales of common stock are made at a price equal to or greater than $0.8581 per share, such that the exchange cap limitation would not apply under applicable Nasdaq rules. Neither the beneficial ownership limitation nor the exchange cap (to the extent applicable under Nasdaq rules) may be amended or waived under the Purchase Agreement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable percentage ownership is based on 2,877,926 shares of our common stock outstanding as of April 8, 2026.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumes the sale of all shares being offered pursuant to this prospectus, including the (i) 519,210 shares of our common stock which we may sell and issue to Tumim from time to time pursuant to the Purchase Agreement, and (ii) 437,012 shares of common stock issuable upon exercise of the Commitment Pre-Funded Warrant.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The business address of Tumim is 2 Wooster Street, 2nd Floor, New York, New York 10013. Tumim&#8217;s principal business is that of a private investor. Maier Joshua Tarlow is the manager of 3i Management, LLC, the general partner of 3i, LP, which is the sole member of Tumim, and has sole voting control and investment discretion over securities beneficially owned directly by Tumim and indirectly by 3i Management, LLC and 3i, LP. 3i Management, LLC is also the manager of Tumim. We have been advised that none of Mr. Tarlow, 3i Management, LLC, 3i, LP, or Tumim is a member of the Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) or an independent broker-dealer, or an affiliate or associated person of a FINRA member or independent broker-dealer. The foregoing should not be construed in and of itself as an admission by Mr. Tarlow as to beneficial ownership of the securities beneficially owned directly by Tumim and indirectly by 3i Management, LLC and 3i, LP.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 437,012 shares of common stock issuable upon the exercise of the Commitment Pre-Funded Warrant, issued to Tumim on February 6, 2026 as commitment warrants in connection with the Purchase Agreement, which was exercisable immediately upon issuance.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B></B></FONT></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B><FONT ID="drs_010"></FONT>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares of common stock offered by this prospectus
are being offered by the Selling Stockholder. The shares may be sold or distributed from time to time by the Selling Stockholder directly
to one or more purchasers or through brokers, dealers, or underwriters who may act solely as agents at market prices prevailing at the
time of sale, at prices related to the prevailing market prices, at negotiated prices, or at fixed prices, which may be changed. The sale
of the shares of our common stock offered by this prospectus could be effected in one or more of the following methods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24px"><TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">ordinary brokers&#8217; transactions;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&#160;</TD><TD>&#160;</TD><TD STYLE="text-align: justify">&#160;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><TD><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">transactions involving cross or block trades;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&#160;</TD><TD>&#160;</TD><TD STYLE="text-align: justify">&#160;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><TD><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">through brokers, dealers, or underwriters who
may act solely as agents;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&#160;</TD><TD>&#160;</TD><TD STYLE="text-align: justify">&#160;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><TD><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8220;at the market&#8221; into an existing
market for the common stock;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&#160;</TD><TD>&#160;</TD><TD STYLE="text-align: justify">&#160;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><TD><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">in other ways not involving market makers or
established business markets, including direct sales to purchasers or sales effected through agents;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&#160;</TD><TD>&#160;</TD><TD STYLE="text-align: justify">&#160;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><TD><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">in privately negotiated transactions; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&#160;</TD><TD>&#160;</TD><TD STYLE="text-align: justify">&#160;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><TD><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any combination of the foregoing.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to comply with the securities laws of
certain states, if applicable, the shares may be sold only through registered or licensed brokers or dealers. In addition, in certain
states, the shares may not be sold unless they have been registered or qualified for sale in the state or an exemption from the state&#8217;s
registration or qualification requirement is available and complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholder is an &#8220;underwriter&#8221;
within the meaning of Section 2(a)(11) of the Securities Act in connection with the resale shares of our common stock under this prospectus.
The Selling Stockholder has informed us that it intends to use one or more registered broker-dealers or agents to effectuate all sales,
if any, of our common stock that it has acquired and may in the future acquire from us pursuant to the Purchase Agreement. Such sales
will be made at prices and at terms then prevailing or at prices related to the then current market price. Each such registered broker-dealer
or agent may be deemed an &#8220;underwriter&#8221; within the meaning of Section&#160;2(a)(11) of the Securities Act. The Selling Stockholder
has informed us that each such broker-dealer or agent will receive commissions from it that will not exceed customary brokerage commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Brokers, dealers, underwriters or agents participating
in the distribution of the shares of our common stock offered by this prospectus may receive compensation in the form of commissions,
discounts, or concessions from the purchasers, for whom the broker-dealers may act as agent, of the shares sold by the Selling Stockholder
through this prospectus. The compensation paid to any such particular broker-dealer by any such purchasers of shares of our common stock
sold by the selling stockholder may be less than or in excess of customary commissions. Neither we nor the selling stockholder can presently
estimate the amount of compensation that any agent will receive from any purchasers of shares of our common stock sold by the Selling
Stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We know of no existing arrangements between the
Selling Stockholder or any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of the shares
of our common stock offered by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may from time to time file with the Commission
one or more supplements to this prospectus or amendments to the registration statement of which this prospectus forms a part to amend,
supplement or update information contained in this prospectus, including, if and when required under the Securities Act, to disclose certain
information relating to a particular sale of shares offered by this prospectus by the Selling Stockholder, including the names of any
brokers, dealers, underwriters or agents participating in the distribution of such shares by the Selling Stockholder, any compensation
paid by the Selling Stockholder to any such brokers, dealers, underwriters or agents, and any other required information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will pay the expenses incident to the registration
under the Securities Act of the offer and sale of the shares of our common stock covered by this prospectus by the Selling Stockholder,
and have agreed to reimburse the Selling Stockholder for the fees and disbursements of its counsel incurred in connection therewith. As
consideration for its irrevocable commitment to purchase our common stock under the Purchase Agreement, we have agreed to pay Tumim a
commitment fee equal to $375,000, which is payable, at our election, in cash or shares of our common stock and pre-funded warrants. We
also have agreed to reimburse the Selling Stockholder for the fees and disbursements of its counsel, payable upon execution of the Purchase
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also have agreed to indemnify the Selling Stockholder
and certain other persons against certain liabilities in connection with the offering of shares of our common stock offered hereby, including
liabilities arising under the Securities Act or, if such indemnity is unavailable, to contribute amounts required to be paid in respect
of such liabilities. The Selling Stockholder has agreed to indemnify us against liabilities under the Securities Act that may arise from
certain written information furnished to us by the Selling Stockholder specifically for use in this prospectus or, if such indemnity is
unavailable, to contribute amounts required to be paid in respect of such liabilities. Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to our directors, officers, and controlling persons, we have been advised that in the opinion
of the Commission this indemnification is against public policy as expressed in the Securities Act and is therefore, unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate that the total expenses for the offering
will be approximately $272,630.74.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholder has represented to us
that at no time prior to the date of the Purchase Agreement has the Selling Stockholder or its agents, representatives or affiliates engaged
in or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule 200 of Regulation SHO
of the Exchange Act) of our common stock or any hedging transaction, which establishes a net short position with respect to our common
stock. The Selling Stockholder has agreed that during the term of the Purchase Agreement, neither the Selling Stockholder , nor any of
its agents, representatives or affiliates will enter into or effect, directly or indirectly, any of the foregoing transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have advised the Selling Stockholder that it
is required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M precludes the Selling
Stockholder, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution from bidding for or
purchasing, or attempting to induce any person to bid for or purchase any security which is the subject of the distribution until the
entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security
in connection with the distribution of that security. All of the foregoing may affect the marketability of the securities offered by this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This offering will terminate on the date that
all shares of our common stock offered by this prospectus have been sold by the Selling Stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is currently listed on the Nasdaq
Capital Market under the symbol &#8220;TIVC.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT ID="drs_011"></FONT>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The validity of the securities offered hereby
will be passed upon for us by Snell &amp; Wilmer L.L.P., San Diego, California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT ID="drs_012"></FONT>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rosenberg Rich Baker Berman, P.A., the Company&#8217;s
independent registered public accounting firm, has audited the Company&#8217;s financial statements at December 31, 2025 and 2024, and
for the years then ended, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise
substantial doubt about the Company&#8217;s ability to continue as a going concern), which is incorporated herein by reference. Such financial
statements are incorporated herein by reference in reliance on Rosenberg Rich Baker Berman P.A.&#8217;s report, given on the authority
of such firm as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT ID="drs_013"></FONT>INTEREST OF NAMED EXPERTS AND COUNSEL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No expert named in the registration statement
of which this prospectus forms a part as having prepared or certified any part thereof (or is named as having prepared or certified a
report or valuation for use in connection with such registration statement) or counsel named in this prospectus as having given an opinion
upon the validity of the securities being offered pursuant to this prospectus or upon other legal matters in connection with the registration
or offering such securities was employed for such purpose on a contingency basis. Also, at the time of such preparation, certification
or opinion or at any time thereafter, through the date of effectiveness of such registration statement or that part of such registration
statement to which such preparation, certification or opinion relates, no such person had, or is to receive, in connection with the offering,
a substantial interest, direct or indirect, in our company. Nor was any such person connected with our company as a promoter, managing
or principal underwriter, voting trustee, director, officer or employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT ID="drs_014"></FONT>DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION
FOR SECURITIES ACT LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to directors, officers or persons controlling the registrant pursuant to the foregoing provisions,
the registrant has been informed that in the opinion of the Commission such indemnification is against public policy as expressed in the
Securities Act and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: center; text-indent: 35.9pt"><B><FONT ID="drs_015"></FONT>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Commission allows us to &#8220;incorporate
by reference&#8221; information from other documents that we file with it into this prospectus, which means that we can disclose important
information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus.
The information incorporated by reference is considered to be a part of this prospectus, and information that we file later with the Commission
will automatically update and supersede information contained in documents filed earlier with the Commission or contained in this prospectus
and the registration statement of which this prospectus is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incorporate by reference into this prospectus
and the registration statement of which this prospectus is a part the information or documents listed below that we have filed with the
Commission:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&#160;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our <A HREF="https://www.sec.gov/Archives/edgar/data/1787740/000143774926010343/tivc20251231_10k.htm">Annual Report on Form 10-K</A> for the fiscal year ended December 31, 2025, filed with the Commission on March 30, 2026;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Current Reports on Form 8-K or Form 8-K/A, as applicable, filed on <A HREF="https://www.sec.gov/Archives/edgar/data/1787740/000168316826000398/tivic_8k.htm">January 20, 2026</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1787740/000168316826000877/tivic_8k.htm">February 9, 2026</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1787740/000168316826001263/tivic_8ka.htm">February 23, 2026</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1787740/000168316826001461/tivic_8k.htm">March 4, 2026</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1787740/000168316826001687/tivic_8k.htm">March 11, 2026</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1787740/000168316826001781/tivic_8k.htm">March 13, 2026</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1787740/000168316826002064/tivic_8k.htm">March 20, 2026</A>, and <A HREF="https://www.sec.gov/Archives/edgar/data/1787740/000143774926009789/tivc20251119_8k.htm">March 25, 2026</A>; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The description of our common stock contained in our registration statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1787740/000110465921136539/tm2132372d1_8a12b.htm">Form 8-A</A> (File No. 001-41052), filed with the Commission under Section 12(b) of the Exchange Act on November 10, 2021, including any amendments or reports filed for the purpose of updating such description, and Exhibit 4.4 to the Company&#8217;s Annual Report on Form 10-K filed with the Commission on March 31, 2022.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also incorporate by reference any future filings
(other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such
items unless such Form 8-K expressly provides to the contrary) made with the Commission pursuant to Sections 13(a), 13(c), 14 or 15(d)
of the Exchange Act, including those made (i) on or after the date of the initial filing of the registration statement of which this prospectus
forms a part and prior to effectiveness of such registration statement, and (ii) on or after the date of this prospectus but prior to
the termination of the offering (i.e., until the earlier of the date on which all of the securities registered hereunder have been sold
or the registration statement of which this prospectus forms a part has been withdrawn). Information in such future filings updates and
supplements the information provided in this prospectus. Any statements in any such future filings will automatically be deemed to modify
and supersede any information in any document we previously filed with the Commission that is incorporated or deemed to be incorporated
herein by reference to the extent that statements in the later filed document modify or replace such earlier statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will furnish without charge to each person,
including any beneficial owner, to whom a prospectus is delivered, upon written or oral request, a copy of any or all of the documents
incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated
by reference into such documents. You should direct any requests for documents to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Tivic Health Systems, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attention: Corporate Secretary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1305 E. Houston Street, Building 1, Suite 311</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">San Antonio, Texas 78205</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may also access these documents, free of charge,
on the Commission&#8217;s website at www.sec.gov or on our website at https://ir.tivichealth.com/. The information contained in, or that
can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus or the registration statement
of which this prospectus is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with Rule 412 of the Securities
Act, any statement contained in a document incorporated by reference herein shall be deemed modified or superseded to the extent that
a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein
modifies or supersedes such statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on information contained
in, or incorporated by reference into, this prospectus and the registration statement of which this prospectus is a part. We have not
authorized anyone to provide you with information different from that contained in this prospectus or incorporated by reference into this
prospectus. The Selling Stockholder is not making offers to sell the securities in any jurisdiction in which such an offer or solicitation
is not authorized or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful
to make such an offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT ID="drs_016"></FONT>WHERE YOU CAN FIND ADDITIONAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have filed with the Commission a registration
statement on Form S-1 under the Securities Act with respect to the shares of our common stock offered by the Selling Stockholder hereby.
This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration
statement or the exhibits filed therewith. For further information about us and the securities offered hereby, reference is made to the
registration statement and the exhibits filed therewith. Statements contained in this prospectus regarding the contents of any contract
or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and in each instance we
refer you to the copy of such contract or other document filed as an exhibit to the registration statement. The Commission also maintains
a website that contains reports, proxy and information statements and other information regarding registrants that file electronically
with the Commission. The address of the website is www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to the periodic reporting requirements
of the Exchange Act, and we file periodic reports, proxy statements and other information with the Commission. These periodic reports,
proxy statements and other information are available on the website of the Commission referred to above. We also maintain a website at
www.tivichealth.com. You may access these materials at our corporate website free of charge as soon as reasonably practicable after they
are electronically filed with, or furnished to, the Commission. Information contained on our corporate website is not a part of this prospectus
and the inclusion of our corporate website address in this prospectus is an inactive textual reference only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<IMG SRC="image_002.jpg" ALT="" STYLE="height: 49px; width: 314px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>956,222 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>April 15, 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 23; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  Q 3H# 2(  A$! Q$!_\0
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MT5CL8/D88$=A7T57R=_P4N_Y-WB_[#%M_P"@O77A(J5>":NKG/B&U2DT1?\
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MP4)_: /PR^'"^$=(N?+\0^(T:.1HS\]O9])&]BWW![;O2MJ&*C7FJ<:,;O\
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G **** "BBB@ HHHH **** $/2D/:BB@!U%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  Q 3H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#1^+_[0W[0
MFB?%GQMIVBW^O)HUIK=[!8K#I0=! L[K&%;RSD;0,')S7(G]IO\ :652S:GX
MB"@9).D# _\ (5?KA6?X@XT+4?\ KWD_]!->S#'4TE%T5_7R/,EA)W;]H_Z^
M9^0ME^VA\==2NX[6S\87]U=2'"0PVD3NQ] H3)K;_P"&FOVE_P#H(^(O_!./
M_C5<Q^QQ_P G4^!?^PA)_P"BI*_9:O0QE:EA9J"I)W7E_D<F&I5,1%R]HU_7
MJ?GQ^R%\;?C9XU^.&E:5XTO-8FT"2"=I4O-.$,98(2N6\L8YQWK]!Z**^?Q%
M:-:?-&*CZ'KT:;I1Y7*X4445S&X5\Z_MU?$SQ+\*/@M'K7A74WTG4SJ4$!N(
MT5CL8/D88$=A7T57R=_P4N_Y-WB_[#%M_P"@O77A(J5>":NKG/B&U2DT1?\
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MP4)_: /PR^'"^$=(N?+\0^(T:.1HS\]O9])&]BWW![;O2MJ&*C7FJ<:,;O\
MKL95</*E%S=1Z?UW/D+P%^U3\?\ XC>,M)\-:/XRNI]1U*X6")?LT.%R>6/R
M< #))] :_6'P[I]UI6@Z?9WM]+JEY! D<U[, 'G<#YG(  &3DX%?$_\ P39_
M9_\ [%T6Y^)VLVV+W45:VTE9!S'!G$DH]"Q&T'T4]FK[IKFS&I3=3V=)))=E
MU-\'":ASS;=PHHHKR3T#P_\ ;-\?:]\-/@!KFO\ AO4'TS5K>:V6*Y158J&F
M56X8$<@D5Y#_ ,$]?CEXW^,=UXU7QAKLNLK8):FW$D:)Y>XR;ON@==H_*N^_
MX*$?\FN>)/\ KXL__2A*\&_X)3_\?GQ$_P"N=E_.6O:I0@\!.;6M]_N/,J2D
ML7&-]+?YGZ$T445XIZ84444 %?,'[2/[=?A;X(WEQH.D0+XH\51?++;1R;8+
M5O25QG+?[*\^I%3_ +='[14_P0^'$6G:)<>3XIU[?!;2J?FMH0/WDP]",@*?
M4Y[5\;?L:?LH2?M"Z]=^)?%$EPOA.RGQ,=Q$FH3_ 'C&&Z@<@LW7G YY'L87
M"T_9O$8CX5T[GG5Z\^?V-'XBOJ'[8'[0?Q?U"2+P]=W\2EN+3PUIY^3VW!6?
M\S5'4/B3^U%X5C%[J%[X]LH4Y\R\MI_+_'<N/SK]7O"O@_1/ ^CPZ5H&E6FD
M:?" $M[.(1J/<XZGW/)K8(# @\@U?]H4HNT**M_7D1]3F]95'<_,+X5_\%+/
M'7AF\BMO&MC;>*=.!"O-%&MM=H/4%1M;Z$#ZU^@_PD^,GA7XV>&(]<\*ZDE[
M;_=F@;Y9K=_[DB=5/Z'L37F/[0W[%_@GXWZ;<W5K90>'?%>TM#JMG$$$C8X$
MR# <>_WAZ]JT_P!EG]E_2?V<O"DD8E74?$U^JG4=1 (5L<B.,'H@S]2>3V R
MQ$\)5I\]-<LNQI1CB*<^2;O'N>WR*7C958H2" P[>]?.O@CP[XY'QUUO0;[X
MHZWJ.E:%;6&H_9Y;2V470F:7=$Y"9"XB'(YY-?1M<EI7@&/2_B/X@\6B\:27
M5[*TLVM2@"Q" R$,&SSGS?3C%<%.:@I)]5V.J<.9Q9\H^'/VH_'<'@'6?#]Y
M&U]XZU>XN&\+WWE#RY+7S94DD? V@V_E.3GJ"G7OZ-X!^*/B?5_ GAR_N]5>
M:ZNM-MIYI"B@N[1*S'@=R37IW@[X)Z5X4\%VNB.Z7][:Q7T-OJDL $L2W4C/
M(%Y.!\P'7G:*S/#/P @\-^&]*TA-:EG2PM(K42M  7"(%SC/&<9KME5H2O:-
MM3EC3K*UWT/6JS_$'_("U'_KVD_]!-:%9_B#_D!:C_U[2?\ H)KS%NCO>Q^/
M/[''_)U/@7_L(2?^BI*_9:OQI_8X_P"3J? O_80D_P#14E?LM7N9O_&CZ?JS
MR\N_AOU_0****\(]4**** "OD[_@I=_R;O%_V&+;_P!!>OK&OD[_ (*7?\F[
MQ?\ 88MO_07KMP7^\0]3FQ/\&7H<+_P2J_Y%#Q]_U_6W_HMZ^ZZ^%/\ @E5_
MR*'C[_K^MO\ T6]?==:9A_O4_E^2(P?\"/\ 74****\X[!",C!K\M/VW_@G?
M? /XOV/C[PJ'L-(U2Z%Y;RVXVBRO5.YD&.@)&\?5AVK]3*X?XT?"G2_C1\.-
M8\*:JH$=Y%F"?;EK>8<I(ON#^8R.]=V#Q'U>JF]GHSEQ-'VT++=;'$_"3QYX
M>_:Z^ +'4H8YEU"W;3]8L0>8)P/FQZ=G4]LCTKX!\":]KO["_P"T[<:=JIDD
MT<2"UO< [;NQ<@I,H[E>&^H9?6I_V8_BEJ_[)/Q_O_"_BK?9Z1<W']G:M"Y.
MR)@?W=P/89!SW5C[5]=_MY_L]I\8OAHOBC0X!/XET")IXC$-S7=K]YXQCJ1]
M]?H0/O5ZRC'"UG1E_#J;?U_70\]MUZ:J+XX'U!INI6NL:=;7UE.ES:7,:S0S
M1G*NC#((/H0:_,?XD?!+QK\<OVX]3\-^)5=8'F6Z>ZB!\J+2EQL*9Z9&%_WR
M?>O6_P#@F_\ M#_VYHLOPQURYS?Z<C3Z1)(>9(,Y>'ZH3D?[)/\ =K[=&F6B
MZBVH"UB%\T0@-R$'F&,$D)NZXR2<5YZE/+JLXVUMH_U.MQCC*<97]1FC:/9^
M'])L],T^!+6QLX5@@AC&%1%&% _ 5=HHKR]SOV"BBB@#YO\ ^"A'_)KGB3_K
MXL__ $H2O!O^"4__ !^?$3_KG9?SEKWG_@H1_P FN>)/^OBS_P#2A*\&_P""
M4_\ Q^?$3_KG9?SEKW:/_(NJ>O\ D>34_P!\AZ?YGZ$T445X1ZP4444 ?DY_
MP4;\43Z[^TA>Z<[DV^CV-O:Q+G(!9/-8X[',F/P%?HE^S#X-MO GP#\$Z7;1
MA#_9L5S,0!EI91YCD^O+$?0"OSJ_X*,>&I]#_:3O[]TVV^K6-M=1-C@[4\IO
MQS'^M?H=^ROXXMOB#\ ?!FIV\JR/'81V=PH/*S1#RW!].5S]"*]_&?[G1Y=O
M^!_PYY&&_P!YJ7W_ .">L4445X!ZX4444 %%%% !1110 5G^(/\ D!:C_P!>
MTG_H)K0JGJ]N]WI5Y!& 9)8710?4J0*:W$]C\=?V./\ DZGP+_V$)/\ T5)7
M[+5^</[.?[$WQ2^''QW\+>*-;TRQATBPNWFGDBOHW95*. 0H.3R17Z/5[&:5
M(5*L7!WT_4\[ PE"FU)6U"BBBO&/2"BBB@ KY._X*7?\F[Q?]ABV_P#07KZQ
MKP+]M3X0>)/C9\'X_#_A:WAN=2&HPW!2>98EV*&!.3QW%=>$DH5X2D[*YSXA
M.5*21XC_ ,$JO^10\??]?UM_Z+>ONNOEK]A#X!>,/@-X>\5VGBZTM[6;4;J"
M6W%O<+-E51@<[>G)%?4M7CIQGB)2B[K_ (!&%BXT8J2LPHHHKA.L**** /AW
M_@H]^SO_ ,)'H$?Q,T.UW:EIB"'5HXUYEMOX93ZE#P?]D_[-=)_P3V_:'_X6
M5X$?P1K=R)?$.@1 0-*V6N;/HIYZE"0I]MM?6VH:?;:K8W%E>0I<VMQ&T4L,
MJ[E=&&"I'<$&OS6\/_LU^,_@W^VUHFE>#C+!I;S'4K;4'4M&NGYQ,DGJ1DQX
M[DJ>XKVJ$XXG#RH5'9QU3/,JQ=&LJL%H]&?3?PU_8OT/X>?M%ZY\0[=HSICH
M9=*TY1C[+/(")C] ,[1_MG^Z*^EJ0=*6O*J59UFG-WMH=\*<::M%!11161H%
M%%% 'S?_ ,%"/^37/$G_ %\6?_I0E>#?\$I_^/SXB?\ 7.R_G+7U)^US\,M=
M^+WP,UGPQX;@BN-6NIK=XXYI1&I"2JS?,>!P#7E/[!W[.7C;X"7/C!_%]G;6
MJZDEL+<V]RLV=ADW9V]/O"O9I5(+ 3@WJWM]QYE2$GBXR2TM_F?7=%%%>,>F
M%%%% 'S!^WA^SK<?&GX=0ZOH=OY_B?0-\T,2CYKF C,D0]6X#*/4$=Z^*?V0
M/VK;O]G/Q'<:1K44UUX0U"8&\MU'[VTE'R^<@]<##+W '<5^NAYKY=_:-_8.
M\*?&F\N-=T2<>%?%$N6EGABW6UTWK)&,8;_:7\0:]G"8NG[-X?$?"_P/-Q&'
MGS^VH[GOW@7XD>&?B7H\6J>&=;L]8LY%W;K:4%E]F7JI]B :Z*25(HV=W5$4
M9+,< "OR4UO]AWXZ_#G4FET739;_ &G"7NA7ZJ6'T+*X_$54G_9^_:5\9D6>
MH:5XJO(L[,:EJ)\L?]]R8Q5O 49.\:RM\O\ ,A8NHM)4W?\ KR/N3]H7]N/P
M3\'M.NK'1KR#Q1XKVE8K*SDWPPMV,L@X !_A!S].M._8S_:HO/VB/#]_::WI
MCVOB#2@IN+NVB(M;A6/!!Z(_JF>V1WQ\X?"/_@F-K^I7<-Y\0M8ATBR4AFT[
M3'$UPX]#)]U?PW5]_?#[X=>'?A;X9MM \,Z9#I>F0#B.(?,[=W=CRS'N36.(
M6$I4_9T_>EW-:+Q%2?//1=CI****\D] **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *S)/^1@A_P"O9_\ T):**:$S3HHHI#"BBB@ HHHH
G **** "BBB@ HHHH **** $/2D/:BB@!U%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
